Although changes in cerebral amyloid burden occurs early and is necessary for an AD diagnosis, the development of tau pathology, both temporally and spatially, more closely aligns with neurodegeneration and clinical symptoms. The gene discussed is MAPT; the disease is Alzheimer disease.